Aphria (NYSE:APHA) released its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02, Briefing.com reports. Aphria had a net margin of 5.75% and a negative return on equity of 0.30%. The company had revenue of $145.70 million during the quarter, compared to the consensus estimate of $159.63 million. During the same quarter in the prior year, the firm posted $0.07 earnings per share. Aphria’s revenue for the quarter was up 15.5% on a year-over-year basis.
NYSE APHA opened at $4.65 on Friday. The stock has a market capitalization of $1.34 billion, a P/E ratio of 51.67 and a beta of 2.19. Aphria has a 52-week low of $1.95 and a 52-week high of $6.44. The firm has a 50-day moving average price of $4.76 and a 200 day moving average price of $4.29. The company has a quick ratio of 3.73, a current ratio of 5.19 and a debt-to-equity ratio of 0.25.
Several equities analysts have issued reports on the stock. Cantor Fitzgerald decreased their price objective on shares of Aphria from $15.50 to $11.75 and set an “overweight” rating for the company in a research note on Friday. Alliance Global Partners restated a “buy” rating and issued a $9.00 price objective on shares of Aphria in a research note on Wednesday, July 15th. Stifel Nicolaus upgraded shares of Aphria from a “hold” rating to a “buy” rating and upped their price objective for the company from $5.30 to $8.00 in a research note on Monday, July 13th. CIBC increased their target price on shares of Aphria from $7.50 to $8.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Pi Financial reiterated a “buy” rating on shares of Aphria in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $8.61.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Read More: Channel Trading
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.